These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32667230)

  • 1. Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions.
    Tanasijevic AM; Revette A; Klepin HD; Zeidan A; Townsley D; DiNardo CD; Sebert M; DeZern AE; Stone RM; Magnavita ES; Chen R; Sekeres MA; Abel GA
    Leuk Lymphoma; 2020 Dec; 61(12):2900-2904. PubMed ID: 32667230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restrictive Versus Liberal Transfusion Strategies in Myelodysplastic Syndrome and Beyond.
    Wilde L; Pan J
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):758-762. PubMed ID: 31678078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes.
    Platzbecker U; Hofbauer LC; Ehninger G; Hölig K
    Leuk Res; 2012 May; 36(5):525-36. PubMed ID: 22300879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes.
    Ryblom H; Hast R; Hellström-Lindberg E; Winterling J; Johansson E
    Eur J Oncol Nurs; 2015 Apr; 19(2):99-106. PubMed ID: 25488465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes.
    Abel GA; Klepin HD; Magnavita ES; Jaung T; Lu W; Shallis RM; Hantel A; Bahl NE; Dellinger-Johnson R; Winer ES; Zeidan AM
    Transfusion; 2021 Oct; 61(10):2830-2836. PubMed ID: 34251040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More concern about transfusion requirement when evaluating quality of life in anemic patients.
    Oliva EN; D'Angelo A; Martino B; Nobile F; Dimitrov BD; Perna A
    J Clin Oncol; 2002 Jul; 20(14):3182-3; author reply 3183-4. PubMed ID: 12118036
    [No Abstract]   [Full Text] [Related]  

  • 7. Infectious disease testing for blood transfusions. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions.
    JAMA; 1995 Nov; 274(17):1374-9. PubMed ID: 7563563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences among hemoglobin thresholds for red blood cell transfusions in patients with hematological diseases in teaching hospitals: a real world data in Japan.
    Yokohama A; Okuyama Y; Ueda Y; Itoh M; Fujiwara SI; Hasegawa Y; Nagai K; Arakawa K; Miyazaki K; Makita M; Watanabe M; Ikeda K; Tanaka A; Fujino K; Matsumoto M; Makino S; Kino S; Takeshita A; Muroi K
    Int J Hematol; 2020 Oct; 112(4):535-543. PubMed ID: 32683598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
    Rojas SM; Díez-Campelo M; Luño E; Cabrero M; Pedro C; Calabuig M; Nomdedeu B; Cedena T; Arrizabalaga B; García M; Cerveró C; Collado R; Azaceta G; Ardanaz MT; Muñoz JA; Xicoy B; Rodríguez MJ; Bargay J; Morell MJ; Simiele A; del Cañizo C
    Leuk Res; 2014 Mar; 38(3):304-9. PubMed ID: 24333115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome.
    Spiriti MA; Latagliata R; Niscola P; Cortelezzi A; Francesconi M; Ferrari D; Volpe E; Clavio M; Grossi A; Reyes MT; Musto P; Mitra ME; Azzarà A; Pagnini D; D'Arena G; Spadano A; Balleari E; Pecorari P; Capochiani E; De Biasi E; Perego D; Monarca B; Pisani F; Scaramella G; Petti MC
    Ann Hematol; 2005 Mar; 84(3):167-76. PubMed ID: 15592833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigue.
    Caocci G; Baccoli R; Ledda A; Littera R; La Nasa G
    Leuk Res; 2007 Feb; 31(2):249-52. PubMed ID: 16814382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
    Alessandrino EP; Amadori S; Barosi G; Cazzola M; Grossi A; Liberato LN; Locatelli F; Marchetti M; Morra E; Rebulla P; Visani G; Tura S;
    Haematologica; 2002 Dec; 87(12):1286-306. PubMed ID: 12495903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
    Leitch HA; Vickars LM
    Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes.
    Jansen AJ; Essink-Bot ML; Beckers EA; Hop WC; Schipperus MR; Van Rhenen DJ
    Br J Haematol; 2003 Apr; 121(2):270-4. PubMed ID: 12694248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials.
    Mo A; McQuilten ZK; Wood EM; Weinkove R
    Intern Med J; 2017 Jun; 47(6):695-698. PubMed ID: 28580745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Red Blood Cell Transfusion Practices for Patients With Cervical Cancer Undergoing Radiotherapy.
    Zayed S; Nguyen TK; Lin C; Boldt G; Beriwal S; Creutzberg CL; Kamrava M; Mendez LC; Velker V; Doll C; Taggar A; Leung E; D'Souza DP
    JAMA Netw Open; 2021 Apr; 4(4):e213531. PubMed ID: 33818620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opinion: To stop the next pandemic, we need to unravel the origins of COVID-19.
    Relman DA
    Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29246-29248. PubMed ID: 33144498
    [No Abstract]   [Full Text] [Related]  

  • 19. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F; Phatak P
    Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physicians' experience in blood supply shortages and the top factors that impact the clinical, economic, and humanistic outcomes of patients with myelodysplastic syndromes in 5 European countries.
    Gupta S; Kulasekararaj AG; Costantino H; Grisolano J; Tang J; Jones S; Tang D
    Curr Med Res Opin; 2023 Feb; 39(2):239-247. PubMed ID: 36453466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.